Oncological PatientsTASTY-trainingNCT07258589
The TASTY-training Study
A study testing Taste and smell training in people with Oncological Patients and Tyrosine Kinase Inhibitor, run by University Medical Center Groningen at 11 sites in Netherlands.
Trial summary
A multicentre non-blinded randomised intervention trial with a parallel cluster design. The multicentre study will be performed at 12 hospitals in the Netherlands. A parallel cluster design per hospital was selected to prevent contact between participants in the same hospital who are randomised into different study… Read more about this study
- Who is it for?
- Ages 18 to 70 years
- Conditions the study is for
- Oncological Patients, Tyrosine Kinase Inhibitor
- What is being tested?
- Taste and smell training
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 90 participants
- Where
- 11 sitesNetherlands
- Study dates
- 10 Nov 2025to Jul 2028
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 70 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Age ≥18 and ≤70 years
- Intention of being treated with tyrosine kinase inhibitors for next 12 weeks.
- Experiencing taste alterations after starting treatment with tyrosine kinase inhibitors
- Consuming solid foods and drinks is possible
- ≤50% of recommended daily intake in kcal consisting of oral nutritional supplements
- Oral mucositis grade ≤2 (Common Terminology Criteria for Adverse Events, version 5.0)
- Ability to comply with all protocol-required actions
- Written informed consent
Who cannot join
- Pregnancy
- History of taste, smell, or saliva production dysfunction before treatment with tyrosine kinase inhibitors
- Previous or current radiotherapy of head and neck region
- Enteral feeding through tube or parenteral feeding
- Participation in another clinical trial aimed at preventing or treating taste and/or smell alterations
- Chronic (>1 month) high dose corticosteroids (>10 mg prednisone/day or equivalent)
Trial locations and contacts
11 sites in 1 country. Contact the study team or a site near you to ask about taking part.
11 sites in 1 country
Netherlands11 sites, 11 recruiting
- Recruiting
Amsterdam UMC
Amsterdam
K. Silverio Alonso-Duin
- Not yet recruiting
Rijnstate Ziekenhuis
Arnhem
M. D.J.L. van der Vorst
- Not yet recruiting
Van Weel-Bethesda Ziekenhuis
Dirksland
H. Noordzij-Nooteboom
- Recruiting
Ziekenhuisvoorzieningen Gelderse Vallei
Ede
G. A. Velders
- Recruiting
University Medical Center Groningen
Groningen, 9713 GZ
J. J.A. de Haan, MD, PhD, +31 50 361 2821, j.j.de.haan@umcg.nl
M. D. Douma, +31 50 361 4603, m.d.douma@umcg.nl
- Recruiting
Martini Ziekenhuis
Groningen
A. W.G. van der Velden
- Not yet recruiting
Radboud University medical Center
Nijmegen
S. Kaal
- Recruiting
Ikazia Ziekenhuis
Rotterdam
F. de Boer
- Recruiting
Ommelander Ziekenhuis Groningen
Scheemda
T. Osinga-Fickweiler
- Not yet recruiting
Maxima Medisch Centrum
Veldhoven
R. van Lieshout
- Not yet recruiting
Isala Klinieken
Zwolle
J. W.B. de Groot
About this study
Official title: Taste and Smell Training in Patients With Cancer Who Are Treated With Tyrosine Kinase Inhibitors: a Multicentre Randomized Intervention Trial
A multicentre non-blinded randomised intervention trial with a parallel cluster design. The multicentre study will be performed at 12 hospitals in the Netherlands. A parallel cluster design per hospital was selected to prevent contact between participants in the same hospital who are randomised into different study arms. Such contact may result in bias as it may allow for patients in the control arm to be informed about elements of taste and smell training.
To examine the effect of at-home taste and smell training versus standard care on taste function and other outcome parameters, measurements will take place at baseline (before the training starts), and after 12 weeks. The intervention will take place at home. The control group will receive usual care. Questionnaires will be filled in online at home, while taste and smell tests and saliva collection will be conducted either at home or in the hospital during regular visits. Patients in both study arms are contacted by their dietitian every 3 weeks.
- Conditions
- Oncological Patients, Tyrosine Kinase Inhibitor
- Being tested
- Taste and smell training
- Keywords
- Taste alterations
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Taste and smell trainingBehavioural
To examine the effect of at-home taste and smell training versus standard care on taste function and other outcome parameters, measurements will take place at baseline (before the training starts), and after 12 weeks. The intervention will take place at home. The control group will receive usual care. Questionnaires will be filled in online at home, while taste and smell tests and saliva collection will be conducted either at home or in the hospital during regular visits. Patients in both study arms are contacted by their dietitian every 3 weeks.
| Study group | Role | What they receive |
|---|---|---|
| Taste and smell training | Experimental | To examine the effect of at-home taste and smell training versus standard care on taste function and other outcome parameters, measurements will take place at baseline (before the training starts), and after 12 weeks. The intervention will take place at home. Receives: Behavioral: Taste and smell training |
| No intervention | No intervention | Standard of care |
What is being measured
The primary outcome is the main question the study is designed to answer.
Taste function
Taste function measured with taste strips at baseline and after week 12 weeks of taste and smell training compared with standard care
Measured: 12 weeks
Secondary outcomes (8)
Smell function
Smell function measured with Sniffin' Sticks at baseline and after week 12 of taste and smell training compared to standard care
Measured: 12 weeks
Food enjoyment in appetite, hunger and sensory perception
Food enjoyment, measured by the subsection of the Appetite, Hunger and Sensory Perception Questionnaire (AHSP) and the Food enjoyment and food liking: questions on food enjoyment and food liking on 9-point hedonic scale at baseline and after 12 weeks of taste and smell training compared with standard care. The AHSP score is lower in presence of malnutrition. Higher scores on the Food enjoyment and food liking indicate more food enjoyment and food liking.
Measured: 12 weeks
Health-related quality of life
The European Organization for Research and Treatment of Cancer Quality of Life Questionnaires Core-30 item (EORTC QLQ-C30 questionnaire) assesses quality of life. It is measured using 1-4 and 1-7 scales. Higher scores indicate better functioning and global quality of life, and worse symptoms on symptom domains.
Measured: 12 weeks
Taste and smell alterations
The Chemotherapy-induced Taste Alteration Scale (ciTAS-NL) assesses taste and smell alterations across intensity, discomfort, and phantogeusia/parageusia domains. It is measured using a 5-point Likert scale. Higher scores indicate more severe alterations.
Measured: 12 weeks
Risk of malnutrition
The Patient-Generated Subjective Global Assessment Short Form (PG-SGA SF) assesses the risk of malnutrition. It is measured using patient-reported items scored numerically. Scores of 0-3 indicate low risk, 4-8 moderate risk, and ≥9 high risk of malnutrition, with higher scores reflecting greater need for nutritional intervention.
Measured: 12 weeks
Dry mouth feeling
The Patient-Generated Subjective Global Assessment Short Form (PG-SGA SF) assesses the risk of malnutrition. It is measured using patient-reported items scored numerically. Scores of 0-3 indicate low risk, 4-8 moderate risk, and ≥9 high risk of malnutrition, with higher scores reflecting greater need for nutritional intervention.
Measured: 12 weeks
Saliva secretion
Saliva secretion
Measured: 12 weeks
Body weight
Body weight
Measured: 12 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted2 Dec 2025
- Study start10 Nov 2025
- Primary completionJul 2028 (estimated)
- Study completionJul 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Oncological PatientsStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Diagnosis
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 90 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University Medical Center Groningen
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- J. J.A. de Haan, MD, PhD, Principal investigator, University Medical Center Groningen
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07258589
- Sponsor's protocol ID
- 20901
- Acronym
- TASTY-training
- Status last verified
- Nov 2025
- First submitted
- 20 Nov 2025
- Last updated
- 15 Jul 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 15 Jul 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Taste and Smell Training in Patients With Cancer Who Are Treated With Tyrosine Kinase Inhibitors: a Multicentre Randomized Intervention Trial
- ClinicalTrials.gov ID
- NCT07258589
- Acronym / sponsor ID
- TASTY-training / 20901
- Conditions
- Oncological Patients, Tyrosine Kinase Inhibitor
- Keywords
- Taste alterations
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 90 participants (estimated)
- Lead sponsor
- University Medical Center GroningenUniversity, hospital or other
- Study start
- 10 Nov 2025 (actual)
- Primary completion
- Jul 2028 (estimated)
- Study completion
- Jul 2028 (estimated)
- First posted
- 2 Dec 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
A multicentre non-blinded randomised intervention trial with a parallel cluster design. The multicentre study will be performed at 12 hospitals in the Netherlands. A parallel cluster design per hospital was selected to prevent contact between participants in the same hospital who are randomised into different study arms. Such contact may result in bias as it may allow for patients in the control arm to be informed about elements of taste and smell training.
To examine the effect of at-home taste and smell training versus standard care on taste function and other outcome parameters, measurements will take place at baseline (before the training starts), and after 12 weeks. The intervention will take place at home. The control group will receive usual care. Questionnaires will be filled in online at home, while taste and smell tests and saliva collection will be conducted either at home or in the hospital during regular visits. Patients in both study arms are contacted by their dietitian every 3 weeks.
Study design
- Primary purpose
- Diagnosis
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Taste and smell training | Experimental | Behavioral: Taste and smell trainingTo examine the effect of at-home taste and smell training versus standard care on taste function and other outcome parameters, measurements will take place at baseline (before the training starts), and after 12 weeks. The intervention will take place at home. |
| No intervention | No intervention | –Standard of care |
Who may qualify
- Ages
- 18 to 70 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (8 listed)
- Age ≥18 and ≤70 years
- Intention of being treated with tyrosine kinase inhibitors for next 12 weeks.
- Experiencing taste alterations after starting treatment with tyrosine kinase inhibitors
- Consuming solid foods and drinks is possible
- ≤50% of recommended daily intake in kcal consisting of oral nutritional supplements
Key exclusion criteria (6 listed)
- Pregnancy
- History of taste, smell, or saliva production dysfunction before treatment with tyrosine kinase inhibitors
- Previous or current radiotherapy of head and neck region
- Enteral feeding through tube or parenteral feeding
- Participation in another clinical trial aimed at preventing or treating taste and/or smell alterations
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Taste and smell trainingTo examine the effect of at-home taste and smell training versus standard care on taste function and other outcome parameters, measurements will take place at baseline (before the training starts), and after 12 weeks. The intervention will take place at home. The control group will receive usual care. Questionnaires will be filled in online at home, while taste and smell tests and saliva collection will be conducted either at home or in the hospital during regular visits. Patients in both study arms are contacted by their dietitian every 3 weeks. | Behavioural | Taste and smell training |
Primary outcome
Taste function
Time frame: 12 weeks
Taste function measured with taste strips at baseline and after week 12 weeks of taste and smell training compared with standard care
8 secondary outcomes
Smell function
Time frame: 12 weeks
Food enjoyment in appetite, hunger and sensory perception
Time frame: 12 weeks
Health-related quality of life
Time frame: 12 weeks
Taste and smell alterations
Time frame: 12 weeks
Risk of malnutrition
Time frame: 12 weeks
Dry mouth feeling
Time frame: 12 weeks
Saliva secretion
Time frame: 12 weeks
Body weight
Time frame: 12 weeks
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 15 Jul 2026.
Related trials for Oncological Patients
Active, not recruitingObservational study
Long-Term Prospective Registry in Prostate Cancer Patients From Diverse Urology Practice Settings Following Prolaris® Testing
Prostate Cancer
RecruitingObservational study
Immunonutrition and Neuromonitoring for Postoperative Delirium in Gynecologic Oncology
Postoperative Delirium (POD), Gynecologic Cancers
Active, not recruitingPhase 1/2
Pilot Study of MC in Paediatric Palliative Care
Palliative Care
Active, not recruiting
Streamlined Geriatric and Oncological Evaluation Based On IC Technology
Breast Cancer, Comorbidities and Coexisting Conditions
Not yet recruiting
Dermatological Effects and Quality of Life in Oncology Patients
Breast Cancer, Ovarian Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
J. J.A. de Haan, MD, PhD principal investigator
University Medical Center Groningen
11 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Taste and smell training in people with Oncological Patients and Tyrosine Kinase Inhibitor, run by University Medical Center Groningen at 11 sites in Netherlands.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 8 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 15 Jul 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 11 sites in Netherlands. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact J. J.A. de Haan, MD, PhD (+31 50 361 2821, j.j.de.haan@umcg.nl), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Taste function (time frame: 12 weeks). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 15 Jul 2026.